Bachem stock holds steady as market value nears CHF 5.7 billion
Published on 08/28/2026 at 10:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bachem Holding AG stock (ISIN CH0012530207) most recently closed at CHF 75.75 on August 27, 2026, on the SIX Swiss Exchange, giving the peptide manufacturer a market capitalization of CHF 5.729 billion in that session.
That latest quote places Bachem shares in a stable trading band in the mid-CHF 70 region, with the August 27, 2026, intraday range reported between CHF 75.75 and CHF 76.10 and no sharp break from prior levels indicated in the available market snapshot.
For investors, the combination of a multi-billion Swiss franc valuation and a relatively tight daily trading range underlines that the market is currently pricing Bachem as a mature growth story where fundamentals and long-term pipeline potential matter more than short-term volatility.
Although the exact 52-week high and low are not specified in the accessible data, the mid-CHF 70 price point at the August 27, 2026, close suggests the shares are trading at a level consistent with a substantial embedded expectation for continued demand in Bachem’s key peptide and oligonucleotide contract manufacturing segments, while leaving room for further re-rating if margins or volumes expand in future reporting periods.
Because Bachem operates in a sector where contract development and manufacturing organizations support both biotech innovators and large pharmaceutical companies, the valuation around CHF 5.729 billion as of late August 2026 can be interpreted as the market’s assessment that recurring revenue and long-term supply agreements will continue to underpin cash flow, justifying a multi-billion capitalization relative to peers in the broader life sciences tools and services space.
Recent trading and market context
In the latest reported SIX Swiss Exchange snapshot for August 27, 2026, Bachem shares finished at CHF 75.75, with the session range narrowly confined between CHF 75.75 and CHF 76.10, a pattern that suggests a period of consolidation rather than a momentum-driven move.
The corresponding market capitalization figure of CHF 5.729 billion at that same date provides a clear yardstick for the company’s size, placing Bachem comfortably in the mid-cap bracket within the Swiss equity universe, where such valuations are often reserved for businesses with established global customer bases and specialized manufacturing capabilities.
From a comparative standpoint, the CHF 75.75 price level on August 27, 2026, juxtaposed with the CHF 5.729 billion market value implies the market is assigning a significant premium per share relative to the company’s historical levels when Bachem was still scaling up its peptide synthesis capacity, and it highlights the extent to which investors now credit the firm’s expanded production footprint and higher-value service offerings.
Assuming the current share count underpinning the August 27, 2026, market capitalization, the implied valuation multiples for Bachem would reflect not only trailing reported results but also expectations for upcoming quarters, particularly in segments such as active pharmaceutical ingredients and custom synthesis, where contract visibility and regulatory track record can support sustained pricing power.
While short-term price fluctuations can be influenced by broad market sentiment or sector rotations, the mid-CHF 70 quote and CHF 5.729 billion valuation reported for August 27, 2026, frame Bachem as a company whose stock performance is closely tied to updates on order intake, capacity utilization, and any new long-term supply contracts that may be disclosed in future investor communications.
Fundamental backdrop and half-year comparison
Current trading levels in late August 2026 build on the fundamental progress Bachem has reported in recent years, including historical revenue growth and profitability improvements that helped the company transition from a niche supplier into a key player in the global peptide and oligonucleotide manufacturing landscape.
In earlier fiscal periods, such as fiscal 2023 and 2024, Bachem’s published financial statements showed rising revenue trends and increasing operating income, reflecting both higher volumes and a shift toward more complex, higher-margin projects; these figures now serve as a reference point rather than a current snapshot, but they underscore why the market assigns a multi-billion market capitalization at the August 27, 2026, close.
Historically, for example, revenue reported in fiscal 2023 reached levels that were materially above prior years, with corresponding improvements in operating profit and margins; this trajectory led investors to expect that subsequent half-year reports for 2025 and 2026 would continue to demonstrate scaling benefits and strong demand from pharmaceutical and biotech customers, although the exact latest half-year numbers must be taken from the most recent interim report once available.
Because the reporting period for Bachem’s latest half-year or quarterly results preceding August 28, 2026, has not been explicitly detailed in the accessible snapshot, investors are currently leaning on historical growth patterns and guidance ranges previously communicated by management, treating those as context rather than definitive current metrics when evaluating whether the CHF 75.75 share price and CHF 5.729 billion market value reported for August 27, 2026, are justified.
In this environment, any forthcoming interim report for 6M/2026 or Q2 2026 will be important for quantifying how revenue, EBITDA, and net income have evolved since the last fiscal year, and for measuring whether Bachem’s ongoing investments in capacity and technology are translating into higher throughput, improved margins, and stronger cash generation relative to the historical baseline.
Investors also watch guidance and analyst consensus closely, looking for concrete figures around expected full-year revenue, operating margin, and capital expenditure, which can then be compared numerically against previous fiscal years to gauge whether Bachem is maintaining its growth trajectory and whether the current share price in the mid-CHF 70 range adequately reflects the company’s forward-looking performance.
Analyst view and sector positioning
Analyst coverage of Bachem generally focuses on the company’s role as a specialized contract manufacturer within the broader life sciences ecosystem, with particular emphasis on its ability to secure multi-year supply agreements and participate in expanding therapeutic markets such as peptide-based drugs and oligonucleotide therapies.
Consensus models typically include forecasts for revenue and EBITDA over the next two to three fiscal years, and these projections are routinely compared to historical baseline figures from previous half-year and full-year reports; this allows investors to quantify expected year-over-year growth and to assess whether the CHF 5.729 billion market capitalization reported at the August 27, 2026, SIX close implies valuation multiples that are aligned with or above sector norms.
If, for instance, analysts project double-digit revenue growth for the next fiscal year and improving EBITDA margins, the implied price-to-earnings and enterprise-value-to-EBITDA ratios based on the CHF 75.75 share price could be evaluated against comparable contract development and manufacturing organizations, with any premium or discount expressed in percentage terms relative to the peer group.
Sector positioning also matters because Bachem competes in a specialized niche where technical expertise, regulatory compliance, and capacity scalability can create barriers to entry; this can justify higher valuation metrics when compared numerically to more commoditized chemical producers, especially if Bachem’s historical financials show consistent margin expansion and strong return on invested capital over multiple reporting periods.
As investors await the next concrete set of half-year or quarterly figures, they will likely scrutinize any changes in consensus estimates, looking for quantified revisions in revenue or earnings-per-share expectations that could drive re-rating of Bachem shares from the CHF 75.75 level reported for August 27, 2026.
Key product: peptide manufacturing services
One representative pillar of Bachem’s business is its peptide manufacturing and related services, through which the company provides active pharmaceutical ingredients and custom synthesis capabilities to global biopharmaceutical clients.
These services cover both research-grade and commercial-scale peptide production, enabling customers to advance drug candidates from early-stage development into clinical trials and, eventually, commercial supply under stringent quality and regulatory standards.
The economic significance of this product and service line is evident in historical reporting periods where revenue growth was driven in part by increased demand for complex peptide APIs, supported by Bachem’s ability to scale production volumes and maintain robust quality systems; this operational strength feeds into investor expectations that future half-year and full-year results will continue to show solid revenue contributions from peptide-related segments.
Moreover, peptide manufacturing services often involve multi-year supply agreements, which can provide visibility into future cash flows and support valuation metrics, helping to explain why, as of the August 27, 2026, SIX trading session, Bachem’s market capitalization stands at CHF 5.729 billion even when near-term volatility is limited and the stock trades in a relatively narrow intraday range around CHF 75.75.
Shares at mid-CHF 70 level
As of August 27, 2026, Bachem shares on the SIX Swiss Exchange were quoted at CHF 75.75, with the day’s range between CHF 75.75 and CHF 76.10, reflecting a steady trading pattern at a price level that aligns with a multi-billion Swiss franc valuation.
Investors who follow Bachem stock can use this latest closing price and the CHF 5.729 billion market capitalization reported for that date as concrete reference points when comparing the company’s valuation against its historical financial performance and the broader life sciences manufacturing sector, while awaiting the next half-year or quarterly report to provide updated revenue and earnings figures.
Fact box
Company: Bachem Holding AG
ISIN: CH0012530207
Ticker: BAHN
Exchange: SIX Swiss Exchange
Price (as of August 27, 2026, 4:00 p.m. local time): CHF 75.75
Market cap: CHF 5.729 billion (as of August 27, 2026)
Sector / Industry: Life sciences tools and services / pharmaceutical contract manufacturing
Index membership: Swiss mid-cap universe
